A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms KEYNOTE-789
- Sponsors Merck Sharp & Dohme
- 10 Dec 2018 Planned primary completion date changed from 29 May 2023 to 15 Jun 2023.
- 14 Nov 2018 Planned End Date changed from 26 Jun 2023 to 15 Jun 2023.
- 26 Sep 2018 Trial design of the study presented at the 19th World Conference on Lung Cancer.